As a Director of Diagnostics at Global Health Labs (GH Labs), John Connelly leverages 20 years of experience in microfluidic device design, isothermal nucleic acid amplification, and lateral flow assays to lead the development of next generation point-of-care diagnostic devices for health systems in low- and middle-income countries.
Prior to GH Labs, John served as a Principal Investigator and, before that, a senior scientist at Global Good, an investment fund of Intellectual Ventures. Previously, John was a senior scientist at Diagnostics For All, a non-profit start-up focused on developing paper-based diagnostic devices with technology originally developed in George Whitesides’ lab at Harvard University.
As a post-doctoral fellow at Cornell University, John also led the successful technology transfer of a waterborne pathogen assay developed by his academic group to Rheonix, Inc’s microfluidic platform.
John earned his PhD, MS, and BS in biological and environmental engineering with minors in food pathogen detection, pharmacology, and toxicology from Cornell University.